Please login to the form below

Not currently logged in

Verastem promotes Robert Forrester to CEO

Takes over from Christoph Westphal who moves to executive chairman

US biotech Verastem has announced a change in personnel at the very top, with Robert Forrester to replace Christoph Westphal as CEO on July 1, while Westphal will become executive chairman.

Forrester currently serves as president and chief operating officer at the company, which specialises in developing drugs to treat cancer by the targeted killing of cancer stem cells.

His positions prior to joining Verastem includes senior roles at life sciences firms Forma Therapeutics, CombinatoR and Coley. He has experience in other industries too, serving at investment banks BZW and UBS, and at investment group MeesPierson.

“Robert's experience and expertise are perfectly suited to advancing our company through clinical development and creating value for shareholders, making this an ideal time to effect this transition,” said Westphal, who also confirmed his own future interest in the company.

“As the largest investor, and with an active 10b5-1 buying plan, Verastem will remain my principal focus. Robert and I will continue to work closely with the board of directors to implement our strategy.”

11th June 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge